Table of Content
1. Executive Summary | Anorexiants Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and Their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyers
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Drug Class, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Drug Class, 2022 to 2032
5.3.1. Catecholamines Anorexiants
5.3.2. Serotonin Anorexiants
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Route of Administration, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Route of Administration, 2022 to 2032
6.3.1. Oral
6.3.2. Subcutaneous
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By End User, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By End User, 2022 to 2032
7.3.1. Institutional Sales
7.3.2. Hospitals
7.3.3. Clinics
7.3.4. Retail Sales
7.3.5. Online Pharmacies
7.3.6. Mail Order Pharmacies
7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. United Kingdom
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By End User
11.4. Key Takeaways
12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By End User
12.4. Key Takeaways
13. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By End User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of Middle East and Africa
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Drug Class
15.1.2.2. By Route of Administration
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Drug Class
15.2.2.2. By Route of Administration
15.2.2.3. By End User
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Drug Class
15.3.2.2. By Route of Administration
15.3.2.3. By End User
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Drug Class
15.4.2.2. By Route of Administration
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Drug Class
15.5.2.2. By Route of Administration
15.5.2.3. By End User
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Drug Class
15.6.2.2. By Route of Administration
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Drug Class
15.7.2.2. By Route of Administration
15.7.2.3. By End User
15.8. United Kingdom
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Drug Class
15.8.2.2. By Route of Administration
15.8.2.3. By End User
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Drug Class
15.9.2.2. By Route of Administration
15.9.2.3. By End User
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Drug Class
15.10.2.2. By Route of Administration
15.10.2.3. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Drug Class
15.11.2.2. By Route of Administration
15.11.2.3. By End User
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Drug Class
15.12.2.2. By Route of Administration
15.12.2.3. By End User
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Drug Class
15.13.2.2. By Route of Administration
15.13.2.3. By End User
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Drug Class
15.14.2.2. By Route of Administration
15.14.2.3. By End User
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Drug Class
15.15.2.2. By Route of Administration
15.15.2.3. By End User
15.16. ASIAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Drug Class
15.16.2.2. By Route of Administration
15.16.2.3. By End User
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Drug Class
15.17.2.2. By Route of Administration
15.17.2.3. By End User
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Drug Class
15.18.2.2. By Route of Administration
15.18.2.3. By End User
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Drug Class
15.19.2.2. By Route of Administration
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Drug Class
15.20.2.2. By Route of Administration
15.20.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Teva Pharmaceuticals
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Janssen Ortho, LLC
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Roche Pharmaceuticals
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Pfizer
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Novo Nordisk A/S
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Abbott Pharmaceuticals PR Ltd.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Epic Pharma, LLC.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Patheon Pharmaceuticals Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Catalent Pharma Solutions, LLC
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Recordati Rare Diseases Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. MOVA Pharmaceuticals
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Volume (Tons) Forecast by Region, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 4: Global Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 5: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 6: Global Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 7: Global Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 8: Global Market Volume (Tons) Forecast by End User, 2017 to 2032
Table 9: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 10: North America Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 11: North America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 12: North America Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 13: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 14: North America Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 15: North America Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 16: North America Market Volume (Tons) Forecast by End User, 2017 to 2032
Table 17: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 18: Latin America Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 19: Latin America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 20: Latin America Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 21: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 22: Latin America Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 23: Latin America Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 24: Latin America Market Volume (Tons) Forecast by End User, 2017 to 2032
Table 25: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 26: Europe Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 27: Europe Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 28: Europe Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 29: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 30: Europe Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 31: Europe Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 32: Europe Market Volume (Tons) Forecast by End User, 2017 to 2032
Table 33: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 34: East Asia Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 35: East Asia Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 36: East Asia Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 37: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 38: East Asia Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 39: East Asia Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 40: East Asia Market Volume (Tons) Forecast by End User, 2017 to 2032
Table 41: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 42: South Asia & Pacific Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 43: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 44: South Asia & Pacific Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 45: South Asia & Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 46: South Asia & Pacific Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 47: South Asia & Pacific Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 48: South Asia & Pacific Market Volume (Tons) Forecast by End User, 2017 to 2032
Table 49: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 50: MEA Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 51: MEA Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 52: MEA Market Volume (Tons) Forecast by Drug Class, 2017 to 2032
Table 53: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 54: MEA Market Volume (Tons) Forecast by Route of Administration, 2017 to 2032
Table 55: MEA Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 56: MEA Market Volume (Tons) Forecast by End User, 2017 to 2032
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by End User, 2022 to 2032
Figure 4: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 6: Global Market Volume (Tons) Analysis by Region, 2017 to 2032
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 10: Global Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 13: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 14: Global Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 17: Global Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 18: Global Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 21: Global Market Attractiveness by Drug Class, 2022 to 2032
Figure 22: Global Market Attractiveness by Route of Administration, 2022 to 2032
Figure 23: Global Market Attractiveness by End User, 2022 to 2032
Figure 24: Global Market Attractiveness by Region, 2022 to 2032
Figure 25: North America Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 26: North America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 27: North America Market Value (US$ Million) by End User, 2022 to 2032
Figure 28: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 29: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 30: North America Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 33: North America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 34: North America Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 37: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 38: North America Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 39: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 40: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 41: North America Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 42: North America Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 43: North America Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 44: North America Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 45: North America Market Attractiveness by Drug Class, 2022 to 2032
Figure 46: North America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 47: North America Market Attractiveness by End User, 2022 to 2032
Figure 48: North America Market Attractiveness by Country, 2022 to 2032
Figure 49: Latin America Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 50: Latin America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 51: Latin America Market Value (US$ Million) by End User, 2022 to 2032
Figure 52: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 53: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 54: Latin America Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 57: Latin America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 58: Latin America Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 61: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 62: Latin America Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 65: Latin America Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 66: Latin America Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 67: Latin America Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 69: Latin America Market Attractiveness by Drug Class, 2022 to 2032
Figure 70: Latin America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 71: Latin America Market Attractiveness by End User, 2022 to 2032
Figure 72: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 73: Europe Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 74: Europe Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 75: Europe Market Value (US$ Million) by End User, 2022 to 2032
Figure 76: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 77: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 78: Europe Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 79: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 80: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 81: Europe Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 82: Europe Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 83: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 84: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 85: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 86: Europe Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 87: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 88: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 89: Europe Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 90: Europe Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 91: Europe Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 92: Europe Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 93: Europe Market Attractiveness by Drug Class, 2022 to 2032
Figure 94: Europe Market Attractiveness by Route of Administration, 2022 to 2032
Figure 95: Europe Market Attractiveness by End User, 2022 to 2032
Figure 96: Europe Market Attractiveness by Country, 2022 to 2032
Figure 97: East Asia Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 98: East Asia Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 99: East Asia Market Value (US$ Million) by End User, 2022 to 2032
Figure 100: East Asia Market Value (US$ Million) by Country, 2022 to 2032
Figure 101: East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 102: East Asia Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 103: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 104: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 105: East Asia Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 106: East Asia Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 107: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 108: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 109: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 110: East Asia Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 111: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 112: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 113: East Asia Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 114: East Asia Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 117: East Asia Market Attractiveness by Drug Class, 2022 to 2032
Figure 118: East Asia Market Attractiveness by Route of Administration, 2022 to 2032
Figure 119: East Asia Market Attractiveness by End User, 2022 to 2032
Figure 120: East Asia Market Attractiveness by Country, 2022 to 2032
Figure 121: South Asia & Pacific Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 122: South Asia & Pacific Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 123: South Asia & Pacific Market Value (US$ Million) by End User, 2022 to 2032
Figure 124: South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 125: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 126: South Asia & Pacific Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 127: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 128: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 129: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 130: South Asia & Pacific Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 131: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 132: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 133: South Asia & Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 134: South Asia & Pacific Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 135: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 136: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 137: South Asia & Pacific Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 138: South Asia & Pacific Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 139: South Asia & Pacific Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 140: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 141: South Asia & Pacific Market Attractiveness by Drug Class, 2022 to 2032
Figure 142: South Asia & Pacific Market Attractiveness by Route of Administration, 2022 to 2032
Figure 143: South Asia & Pacific Market Attractiveness by End User, 2022 to 2032
Figure 144: South Asia & Pacific Market Attractiveness by Country, 2022 to 2032
Figure 145: MEA Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 146: MEA Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 147: MEA Market Value (US$ Million) by End User, 2022 to 2032
Figure 148: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 149: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 150: MEA Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 151: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 152: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 153: MEA Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 154: MEA Market Volume (Tons) Analysis by Drug Class, 2017 to 2032
Figure 155: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 157: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 158: MEA Market Volume (Tons) Analysis by Route of Administration, 2017 to 2032
Figure 159: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 160: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 161: MEA Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 162: MEA Market Volume (Tons) Analysis by End User, 2017 to 2032
Figure 163: MEA Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 164: MEA Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 165: MEA Market Attractiveness by Drug Class, 2022 to 2032
Figure 166: MEA Market Attractiveness by Route of Administration, 2022 to 2032
Figure 167: MEA Market Attractiveness by End User, 2022 to 2032
Figure 168: MEA Market Attractiveness by Country, 2022 to 2032
